Shin Nippon Biomedical Laboratories, Ltd. Share Price Deutsche Boerse AG
Equities
YB3
JP3379950003
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.55 EUR | -5.62% | +0.67% | -28.10% |
Sales 2024 | 2.64TCr 17Cr 16Cr 1.4TCr | Sales 2025 * | 3.05TCr 19Cr 18Cr 1.62TCr | Capitalization | 5.85TCr 37Cr 34Cr 3.1TCr |
---|---|---|---|---|---|
Net income 2024 | 553.1Cr 3.52Cr 3.24Cr 293.3Cr | Net income 2025 * | 430Cr 2.74Cr 2.52Cr 228.02Cr | EV / Sales 2024 | 2.39 x |
Net Debt 2024 * | 1.95TCr 12Cr 11Cr 1.03TCr | Net Debt 2025 * | 2.28TCr 14Cr 13Cr 1.21TCr | EV / Sales 2025 * | 2.66 x |
P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
13.6
x | Employees | 1,341 |
Yield 2024 |
3.29% | Yield 2025 * |
3.56% | Free-Float | 48.8% |
1 day | -5.63% | ||
1 week | +0.67% | ||
Current month | -15.64% | ||
1 month | -13.22% | ||
3 months | -23.35% | ||
6 months | -21.76% | ||
Current year | -28.10% |
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 01/81/01 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 01/02/01 |
Terumasa Hirai
CMP | Compliance Officer | - | 01/84/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 01/81/01 |
Ichiro Nagata
BRD | Director/Board Member | 38 | 01/17/01 |
Sales & Marketing | 64 | 01/02/01 |
Date | Price | Change |
---|---|---|
29/24/29 | 7.55 | -5.62% |
28/24/28 | 8 | +3.23% |
27/24/27 | 7.75 | +4.03% |
24/24/24 | 7.45 | -2.61% |
23/24/23 | 7.65 | +2.00% |
Delayed Quote Deutsche Boerse AG, May 29, 2024 at 11:37 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.05% | 5.87TCr | |
-2.02% | 4.13TCr | |
+37.12% | 3.92TCr | |
-10.22% | 2.74TCr | |
+13.42% | 2.65TCr | |
-21.60% | 1.9TCr | |
+2.89% | 1.25TCr | |
+22.40% | 1.19TCr | |
+27.49% | 1.21TCr |
- Stock Market
- Equities
- 2395 Stock
- YB3 Stock